Sygnature Chemical Services and Heptares Therapeutics have entered a drug-discovery collaboration.
Under the terms of the agreement, scientists from the two companies are working together to advance one of Heptares' internal high-value GPCR programmes.
Sygnature will provide synthetic chemistry services to produce a novel chemical library for Heptares to evaluate against purified, stabilised and functional proprietary GPCR targets (known as Stars stabilised receptors).
